Answers are grounded in this paper and cite their sources.
OBJECTIVES: To determine whether prospective genotype-guided drug selection and dosing can reduce cumulative withdrawal severity and improve treatment tolerability in alcohol withdrawal syndrome (AWS) complicated by seizures. METHODS: In this single-center, parallel-group randomized clinical trial, 100 inpatients with AWS and seizures were allocated 1:1 to a genotype-guided prescribing strategy or control. All patients were genotyped on admission for CYP2D6*4, CYP2C19*2, CYP2C19*17, CYP3A4*1B, CYP3A5*3, and ABCB1 3435C>T. Intervention-group physicians received an individualized report with recommendations on benzodiazepine and anticonvulsant selection and starting dose; control-group physicians received a format-matched report without individualized recommendations. The primary outcome was area under the CIWA-Ar curve over 0-72 h, assessed by a blinded rater. RESULTS: AUC CIWA-Ar was 774.3 ± 175.9 vs. 903.6 ± 199.5 score-hours (mean difference -129.3; 95 % CI -204.0 to -54.6; p<0.001). Confirmed stabilization by 48 h occurred in 31/50 vs. 20/50 patients (log-rank p=0.020; Benjamini-Hochberg-adjusted p=0.051, not significant after multiplicity correction). UKU side-effect scores were lower on days 3 and 5 (both p<0.001), and excessive sedation occurred in 1/50 vs. 9/50 patients (p=0.016). Total benzodiazepine load was lower with genotype guidance (25.0 vs. 27.5 mg diazepam equivalents; p=0.016). The composite rate of clinically significant adverse events and the rates of delirium and unplanned treatment modification did not differ significantly. CONCLUSIONS: A prospective genotype-informed prescribing strategy was associated with lower cumulative withdrawal severity and less excessive sedation while using a lower benzodiazepine load. Because the intervention also changed anticonvulsant selection and drug concentrations were not measured, these findings support the clinical strategy as a whole rather than any single genotype-to-dose rule. Multicenter, prospectively registered trials with measured drug exposure are warranted.
No takes yet. Share an insight, caveat, or question.
Skryabin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: